Early Prediction for Sepsis Induced Acute Lung InjuryNCT04541264
Radiomics Markers to Predict Sepsis Induced Acute Respiratory Distress Syndrome
An observational study of Early Prediction for Sepsis Induced Acute Lung Injury, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University at 1 site in China.
Trial summary
Introduction: Sepsis-induced acute respiratory distress syndrome(SI-ARDS) is a common complication of severe sepsis and is an independent contributor to poor prognosis of patients. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Early Prediction for Sepsis Induced Acute Lung Injury
- What is being tested?
- radiomic of chest CT
- How many people
- 300 participants
- Where
- 1 siteChina
- Study dates
- 1 Jun 2021to 31 Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: We plan to recruit 160 patients in discovering group, 40 patients in internal validation, and 100 patients in external validation group. Patients between 18 and 80 years of age with sepsis and septic shock will be screened for eligibility
Who may be able to join
- Clinical diagnosis of sepsis
- Clinical diagnosis of ARDS
- Written informed consent in external validation cohort
Who cannot join
- admission stay <24hours,
- the presence of end-stage lung disease or long-term oxygen therapy,
- critically ill patients who have started mechanical ventilation caused by SA-ARDS before admission,
- a history of lung transplantation and chronic obstructive pulmonary disease,
- cancer patients not/have received chemotherapy
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510000
Li Li, 02034071029, lil3@mail.sysu.edu.cn
About this study
Official title: Application of Radiomics as Predicted Marker for Patients With Sepsis Induced Acute Respiratory Distress Syndrome:a Protocol for an Observational Ambispective Cohort Study
Introduction:
Sepsis-induced acute respiratory distress syndrome(SI-ARDS) is a common complication of severe sepsis and is an independent contributor to poor prognosis of patients. It remains a clinical challenge to identify the SI-ARDS early and accurately, which could optimize the treatment strategy and reduce the mortality risk. Radiomics high-dimensional features extracted from CT images offer an insight into microvascular damage of SI-ARDS that are imperceptible to human eyes and aspects of intra-alveolar heterogeneity with potential prognostic relevance.
Read more
Methods:
Study design Investigators screened all patients with sepsis and septic shock who are treated in Sun Yat-sen Memorial Hospital, Sun Yat-sen University during the period from 1 May 2015 and 30 May 2022. Patients were recruited retrospectively from May 2015 to April 2021 as discovering group, and prospectively during the period from May 2021 to May 2022 as validation group. Follow-up will conducted until April 2023.
Cohort descriptions and definitions Investigators plan to recruit 160 patients in discovering group, 40 patients in internal validation group, and 100 patients in external validation group. Patients between 18 and 80 years of age with sepsis and septic shock will be screened for eligibility. SI-ARDS is defined by sequential occurrence of the sepsis-3 consensus criteria for sepsis and the Berlin Definition for ARDS. The exclusion criteria are:
- admission stay <24hours,
- the presence of end-stage lung disease or long-term oxygen therapy,
- critically ill patients who have started mechanical ventilation caused by SI-ARDS before admission,
- a history of lung transplantation and chronic obstructive pulmonary disease,
- cancer patients not/have received chemotherapy.
Outcome measures In this study, the primary outcome measure was the occurrence rates of acute respiratory distress syndrome(ARDS). It refers to the occurrence of sepsis patients progressed into ARDS.
Secondary outcome measures were as follows:
1.28-day mortality 2.ventilator-free days 3.respiratory failure-free days
Data collection All clinical data were collected by investigators and trained personnel. Each participant's data will be filled in electronic case report forms (CRF) and store online using REDCap (Research Electronic Data Capture).
Discussion:
SI-ARDS is one common severe complication with critically ill sepsis patients, which causes high mortality and poor prognosis. Early ARDS patient(arterial oxygen tension/inspired oxygen fraction [PaO2/FIO2] ≤ 300 mmHg but > 200 mmHg) may not require invasive mechanical ventilation, and is more readily reversible than acute respiratory distress syndrome(ARDS). In this ambispecive cohort study, investigators developed and validated novel nomograms incorporating the radiomics signature and clinical signature to provide an easy-to-use and individualized prediction of SI-ARDS occurrence and severe degree in patients with early stage.
- Being tested
- radiomic of chest CT
- Keywords
- radiomics, sepsis, acute respiratory distress syndrome, deep learning, prediction model
- Medical subject headings
- Sepsis, Respiratory Distress Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
radiomic of chest CTDiagnostic test
radiomics as a quantitative imaging method for early detection, risk assessment, and treatment decisions for early predicting sepsis induced acute respiratory distress syndrome.
| Study group | Role | What they receive |
|---|---|---|
| Model reconstruction cohort | 160 patients were recruited retrospectively from May 2015 to April 2020 as discovering group. Receives: Diagnostic Test: radiomic of chest CT | |
| Internal validation cohort | 40 patients were recruited retrospectively from May 2015 to April 2020 as internal validation group. Receives: Diagnostic Test: radiomic of chest CT | |
| External validation cohort | 100 patients will be recruited prospectively during the period from May 2020 to April 2021 as external validation group. Receives: Diagnostic Test: radiomic of chest CT |
What is being measured
The primary outcome is the main question the study is designed to answer.
occurrence rates of acute respiratory distress syndrome(ARDS)
It refers to the occurrence of sepsis patients progressed into ARDS in all patients enrolled into the study
Measured: from date of admission until the date of disease progressing to ARDS, assessed up to 28days
Secondary outcomes (3)
28-day mortality
a cox proportion hazards regression model was used to analysis the survival outcome of patients with sepsis within 28 days according to radiomics characteristics
Measured: from date of admission until the date of death from any cause, assessed up to 28days
ventilator-free days
defined as the number of calendar days after initiating ventilator unassisted breathing to day 28 after admission
Measured: from date of admission until the date of ventilation or discharge from hospital, assessed up to 28days
respiratory failure-free days
defined as the day without evidence of non-respiratory organ failure
Measured: from date of admission until the initiating date of respiratory failure, assessed up to 28days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Sep 2020
- Study start1 Jun 2021
- Primary completion17 Aug 2023 (estimated)
- Study completion31 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Early Prediction for Sepsis Induced Acute Lung InjuryStudies of the same condition, open and under way.
- More trials run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Li Li, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04541264
- Sponsor's protocol ID
- SYSEC-KY-KS-2020-122
- Status last verified
- Jun 2021
- First submitted
- 27 Aug 2020
- Last updated
- 18 Jun 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Individual participant data in this research can contact lil3@mail.sysu.edu.cn for reasonable requests.
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Application of Radiomics as Predicted Marker for Patients With Sepsis Induced Acute Respiratory Distress Syndrome:a Protocol for an Observational Ambispective Cohort Study
- ClinicalTrials.gov ID
- NCT04541264
- Acronym / sponsor ID
- SYSEC-KY-KS-2020-122
- Keywords
- radiomics, sepsis, acute respiratory distress syndrome, deep learning, prediction model
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityUniversity, hospital or other
- Study start
- 1 Jun 2021 (actual)
- Primary completion
- 17 Aug 2023 (estimated)
- Study completion
- 31 Dec 2023 (estimated)
- First posted
- 9 Sep 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Introduction:
Sepsis-induced acute respiratory distress syndrome(SI-ARDS) is a common complication of severe sepsis and is an independent contributor to poor prognosis of patients. It remains a clinical challenge to identify the SI-ARDS early and accurately, which could optimize the treatment strategy and reduce the mortality risk. Radiomics high-dimensional features extracted from CT images offer an insight into microvascular damage of SI-ARDS that are imperceptible to human eyes and aspects of intra-alveolar heterogeneity with potential prognostic relevance.
Methods:
Study design Investigators screened all patients with sepsis and septic shock who are treated in Sun Yat-sen Memorial Hospital, Sun Yat-sen University during the period from 1 May 2015 and 30 May 2022. Patients were recruited retrospectively from May 2015 to April 2021 as discovering group, and prospectively during the period from May 2021 to May 2022 as validation group. Follow-up will conducted until April 2023.
Cohort descriptions and definitions Investigators plan to recruit 160 patients in discovering group, 40 patients in internal validation group, and 100 patients in external validation group. Patients between 18 and 80 years of age with sepsis and septic shock will be screened for eligibility. SI-ARDS is defined by sequential occurrence of the sepsis-3 consensus criteria for sepsis and the Berlin Definition for ARDS. The exclusion criteria are:
- admission stay <24hours,
- the presence of end-stage lung disease or long-term oxygen therapy,
- critically ill patients who have started mechanical ventilation caused by SI-ARDS before admission,
- a history of lung transplantation and chronic obstructive pulmonary disease,
- cancer patients not/have received chemotherapy.
Outcome measures In this study, the primary outcome measure was the occurrence rates of acute respiratory distress syndrome(ARDS). It refers to the occurrence of sepsis patients progressed into ARDS.
Secondary outcome measures were as follows:
1.28-day mortality 2.ventilator-free days 3.respiratory failure-free days
Data collection All clinical data were collected by investigators and trained personnel. Each participant's data will be filled in electronic case report forms (CRF) and store online using REDCap (Research Electronic Data Capture).
Discussion:
SI-ARDS is one common severe complication with critically ill sepsis patients, which causes high mortality and poor prognosis. Early ARDS patient(arterial oxygen tension/inspired oxygen fraction [PaO2/FIO2] ≤ 300 mmHg but > 200 mmHg) may not require invasive mechanical ventilation, and is more readily reversible than acute respiratory distress syndrome(ARDS). In this ambispecive cohort study, investigators developed and validated novel nomograms incorporating the radiomics signature and clinical signature to provide an easy-to-use and individualized prediction of SI-ARDS occurrence and severe degree in patients with early stage.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Model reconstruction cohort | – | Diagnostic Test: radiomic of chest CT160 patients were recruited retrospectively from May 2015 to April 2020 as discovering group. |
| Internal validation cohort | – | Diagnostic Test: radiomic of chest CT40 patients were recruited retrospectively from May 2015 to April 2020 as internal validation group. |
| External validation cohort | – | Diagnostic Test: radiomic of chest CT100 patients will be recruited prospectively during the period from May 2020 to April 2021 as external validation group. |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- We plan to recruit 160 patients in discovering group, 40 patients in internal validation, and 100 patients in external validation group. Patients between 18 and 80 years of age with sepsis and septic shock will be screened for eligibility
Key inclusion criteria (3 listed)
- Clinical diagnosis of sepsis
- Clinical diagnosis of ARDS
- Written informed consent in external validation cohort
Key exclusion criteria (5 listed)
- admission stay <24hours,
- the presence of end-stage lung disease or long-term oxygen therapy,
- critically ill patients who have started mechanical ventilation caused by SA-ARDS before admission,
- a history of lung transplantation and chronic obstructive pulmonary disease,
- cancer patients not/have received chemotherapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| radiomic of chest CTradiomics as a quantitative imaging method for early detection, risk assessment, and treatment decisions for early predicting sepsis induced acute respiratory distress syndrome. | Diagnostic test | External validation cohort, Internal validation cohort, Model reconstruction cohort |
Primary outcome
occurrence rates of acute respiratory distress syndrome(ARDS)
Time frame: from date of admission until the date of disease progressing to ARDS, assessed up to 28days
It refers to the occurrence of sepsis patients progressed into ARDS in all patients enrolled into the study
3 secondary outcomes
28-day mortality
Time frame: from date of admission until the date of death from any cause, assessed up to 28days
ventilator-free days
Time frame: from date of admission until the date of ventilation or discharge from hospital, assessed up to 28days
respiratory failure-free days
Time frame: from date of admission until the initiating date of respiratory failure, assessed up to 28days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2021.
- Individual participant dataSharing planned: Undecided. Individual participant data in this research can contact lil3@mail.sysu.edu.cn for reasonable requests.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Early Prediction for Sepsis Induced Acute Lung Injury, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact LI LI (02034071029, lil3@mail.sysu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
occurrence rates of acute respiratory distress syndrome(ARDS) (time frame: from date of admission until the date of disease progressing to ARDS, assessed up to 28days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2021.